Financial
FY2025 revenue $2.58bn (+0.7%); operating margin 1.8%; net income $759.9m.
Net income lifted by non-operating investment gains; operating profit was $47m.
Bio-Rad Laboratories
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Fair
Customer rating
No reviews yet
Financial health
Band: FairListed: BIO
FY2025 revenue $2.58bn (+0.7%); operating margin 1.8%; net income $759.9m.
Net income lifted by non-operating investment gains; operating profit was $47m.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$2.6bn | +0.7% | US$47.2m | US$759.9m | Bio-Rad Laboratories |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Jul 2026: Bio-Rad began a global restructuring involving job cuts, consolidation of functions and facility closures, with estimated pre-tax charges of $80–90m, to be substantially complete by end of 2027, according to its SEC filing.
Cyber & information governance
No confirmed data breaches, cyber incidents or regulator action involving Bio-Rad Laboratories found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
No product recalls, FDA warning letters or safety notices involving Bio-Rad Laboratories found in HSH's search of the last 24 months.
Contract performance
No customer contract disputes, terminations or troubled implementations involving Bio-Rad Laboratories found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.